SS-31 (Elamipretide): Mitochondrial Peptide Research Guide

Understanding SS-31 Peptide: A Mitochondria-Targeting Therapeutic

SS-31 peptide, also known as elamipretide, Bendavia, or MTP-131, represents a novel class of mitochondria-targeting therapeutics that has garnered significant attention in biomedical research over the past two decades. This synthetic tetrapeptide with the sequence H-D-Arg-Dmt-Lys-Phe-NH2 was initially discovered during opioid receptor studies and has since emerged as one of the most extensively studied mitochondrial protective compounds in scientific literature.

The SS-31 peptide’s unique ability to selectively target and accumulate in the inner mitochondrial membrane, where it interacts with cardiolipin—a phospholipid critical for mitochondrial structure and function—has positioned SS-31 peptide as a promising research tool for investigating mitochondrial dysfunction across multiple disease models. With over 150 peer-reviewed publications examining its effects, the SS-31 peptide has been explored in preclinical and clinical studies for conditions ranging from cardiac myopathies to neurodegenerative diseases and aging-related skeletal muscle dysfunction.

SS-31 Peptide: Molecular Structure and Cardiolipin Binding Mechanism

The therapeutic potential of SS-31 peptide stems from its highly specific interaction with cardiolipin, a unique dimeric phospholipid found predominantly in the inner mitochondrial membrane. Unlike traditional antioxidants such as Vitamin E, Vitamin A, or even other mitochondria-targeted compounds like MitoQ and Coenzyme Q10, SS-31 peptide exhibits superior mitochondrial targeting efficiency and lower toxicity profiles in research models.

The SS-31 peptide contains dimethyl tyrosine residues that enable it to interact with oxygen radicals, forming unreactive tyrosine radicals that subsequently couple together to form di-tyrosine. This mechanism allows SS-31 peptide to scavenge reactive oxygen species while simultaneously protecting cardiolipin from peroxidation—a critical factor in maintaining mitochondrial membrane integrity and function.

Cardiolipin-Protein Complex Assembly

Recent investigations using chemical cross-linking with mass spectrometry have identified specific protein interactors of SS-31 peptide in mitochondria. The identified proteins fall into two functional categories: those involved in ATP production through the oxidative phosphorylation pathway, and those involved in 2-oxoglutarate metabolic processes. All identified SS-31 peptide-interacting proteins are known cardiolipin binders, suggesting that the peptide’s effects are mediated through modulation of cardiolipin-dependent protein assemblies.

Research published in the Proceedings of the National Academy of Sciences demonstrates that SS-31 peptide binding to cardiolipin modulates mitochondrial membrane electrostatic potentials and facilitates the assembly of respiratory chain supercomplexes. These structural changes contribute to improved electron transport chain efficiency, reduced proton leakage, and enhanced ATP synthesis capacity—effects that have been consistently observed across multiple research models.

SS-31 Peptide Pharmacokinetics and Distribution Profile

Pharmacokinetic studies in animal models reveal that SS-31 peptide is a cell-permeable compound that distributes rapidly throughout the body following administration. The SS-31 peptide shows highest concentrations in kidneys, followed by heart, liver, lungs, and skeletal muscle tissue. Research in rats, dogs, and monkeys indicates an elimination half-life of approximately 2 hours, with complete renal excretion—100% of the SS-31 peptide and its metabolites are detected in urine.

Importantly, SS-31 peptide accumulates specifically in the inner mitochondrial membrane and is not transported into the mitochondrial matrix, even at very high concentrations. This selective localization contributes to its favorable safety profile, as the SS-31 peptide demonstrates no adverse effects on healthy mitochondria in research settings. The compound’s water-soluble nature and efficient tissue penetration make it an attractive candidate for investigating mitochondrial function across diverse organ systems.

Clinical Research Applications of SS-31 Peptide

Barth Syndrome and Cardiolipin Metabolism

One of the most significant clinical developments involving SS-31 peptide occurred in 2025 when the FDA approved elamipretide for the treatment of Barth syndrome—a rare X-linked genetic disorder caused by mutations in the TAFAZZIN gene. These mutations lead to cardiolipin abnormalities and subsequent mitochondrial dysfunction affecting energy production throughout the body, particularly in cardiac and skeletal muscle.

Research conducted at Johns Hopkins Medicine demonstrated that SS-31 peptide treatment improved energy production and assembly of important protein complexes in mitochondria of Barth syndrome cell models. A subsequent 28-week randomized, double-blind, placebo-controlled clinical trial, followed by an extension phase, showed that patients receiving SS-31 peptide experienced significant improvements in the 6-Minute Walk Test, Barth Syndrome Symptom Assessment Scale scores, and cardiac physiology parameters.

Heart Failure and Cardiac Function

Clinical trials investigating SS-31 peptide in heart failure have yielded mixed results, highlighting the complexity of mitochondrial dysfunction in cardiovascular disease. A Phase I study enrolling 36 heart failure patients found that a 4-hour infusion of high-dose SS-31 peptide resulted in favorable changes, including significant reductions in left ventricular volumes. Biomarker studies demonstrated decreased levels of high temperature requirement serine peptidase 2 (HtrA2)—a mitochondrial protein associated with cardiomyocyte apoptosis—in patients treated with SS-31 peptide.

However, a larger Phase 2 trial enrolling 71 patients with reduced ejection fraction found that SS-31 peptide treatment for 28 days did not significantly alter left ventricular end systolic volume from baseline. Research in animal models has shown more consistent benefits, with SS-31 peptide treatment ameliorating cardiac mitochondrial morphology and defective mitophagy in murine models while improving mitochondrial respiratory efficiency and supercomplex organization.

Skeletal Muscle Aging and Exercise Tolerance

Some of the most compelling research findings involve SS-31 peptide’s effects on age-related skeletal muscle dysfunction. Studies published in Free Radical Biology and Medicine demonstrate that prolonged SS-31 peptide treatment reverses energetic deficits in aged mitochondria and improves both resting and dynamic skeletal muscle function. Treated animals showed increased mitochondrial ATP production capacity, restoration of redox homeostasis, and reversal of cysteine S-glutathionylation post-translational modifications across the skeletal muscle proteome.

The functional benefits translated to measurably improved exercise performance—gastrocnemius muscles in SS-31 peptide-treated aged mice exhibited greater fatigue resistance, increased mass, and contributed to significant improvements in treadmill endurance compared to both pretreatment baseline and untreated control values. These improvements occurred without increases in mitochondrial content, suggesting that SS-31 peptide enhances mitochondrial quality rather than quantity.

Adenine Nucleotide Translocator Function

Recent research published in Geroscience has elucidated a specific mechanism through which SS-31 peptide improves aged mitochondrial function. The SS-31 peptide binds directly to the adenine nucleotide translocator (ANT), a critical protein responsible for ADP/ATP exchange across the mitochondrial membrane. In aged muscle mitochondria, SS-31 peptide treatment increases ADP sensitivity by enhancing uptake through the ANT, thereby improving the efficiency of ATP synthesis.

This improvement in ADP sensitivity correlates with rescued muscle force production and cardiac systolic function in aged animals. The mechanism appears to involve decreased protein S-glutathionylation of ANT and other proteins in the ADP/ATP transport and synthesis pathway, without changes in protein abundance. This rapid modifiability of mitochondrial ADP sensitivity by SS-31 peptide represents a novel therapeutic avenue for addressing age-related energetic decline.

Renal Protection and Kidney Disease

Given that SS-31 peptide achieves its highest tissue concentrations in kidneys, substantial research has examined its potential in renal diseases. The SS-31 peptide accumulates primarily in the inner mitochondrial membrane of renal cells and has demonstrated protective effects against various forms of kidney injury in preclinical models. Research published in the journal on kidney diseases indicates that SS-31 peptide decreases mitochondrial reactive oxygen species production, restores mitochondrial structure, promotes ATP synthesis, and reduces electron leakage in kidney tissue.

The SS-31 peptide has shown promise in models of ischemia-reperfusion injury, diabetic nephropathy, and other conditions characterized by mitochondrial dysfunction. Clinical studies have identified injection site reactions as the primary adverse effects of SS-31 peptide, with most being mild in severity. The peptide’s complete renal excretion and favorable safety profile in kidney tissue make SS-31 peptide particularly relevant for investigating mitochondrial contributions to renal pathophysiology.

MicroRNA-133a and SS-31 Peptide in Cardiac Remodeling

Recent research has begun exploring potential interactions between SS-31 peptide’s mitochondrial effects and microRNA regulation in cardiac tissue, particularly focusing on miR-133a—a muscle-specific microRNA that plays crucial roles in cardiac development, hypertrophy, and remodeling. MicroRNA-133a is known to regulate multiple pathways involved in cardiac hypertrophy by targeting proteins such as RhoA, Cdc42, calcineurin, and components of the IGF-1/PI3K/Akt signaling cascade.

In pathological cardiac remodeling, miR-133a expression typically decreases, which correlates with activation of hypertrophic signaling pathways. Research published in Nature Medicine demonstrates that miR-133a can protect cardiomyocytes against hypertrophy induced by various stimuli through its multi-targeting effects on downstream signaling pathways. The microRNA also influences cardiac fibrosis by regulating TGF-β/Smad signaling and connective tissue growth factor expression.

Integrating Mitochondrial and Gene Expression Regulation

While SS-31 peptide primarily acts through direct mitochondrial mechanisms, and miR-133a operates through post-transcriptional gene regulation, both pathways converge on maintaining cardiac function under stress conditions. The calcineurin/NFAT signaling pathway, which is inhibited by miR-133a, also inversely regulates miR-133a expression, creating a reciprocal feedback loop that modulates cardiac hypertrophy progression.

Research suggests that SIRT1, a NAD+-dependent deacetylase involved in mitochondrial biogenesis and function, is a direct target of miR-133a regulation. This connection hints at potential crosstalk between microRNA-mediated gene regulation and mitochondrial function—domains where SS-31 peptide’s effects on mitochondrial energetics might indirectly influence cellular signaling pathways regulated by miR-133a.

Understanding how mitochondrial peptides like SS-31 peptide might influence or interact with microRNA-regulated pathways represents an emerging area of investigation that could provide insights into comprehensive approaches for addressing cardiac dysfunction at both the organellar and transcriptional levels.

SS-31 Peptide Safety Profile and Clinical Observations

Clinical studies to date indicate that SS-31 peptide treatment is generally well-tolerated, with injection site reactions representing the most commonly reported adverse effect. In clinical trials, erythema occurred in 57% of patients receiving SS-31 peptide, pruritus in 47%, pain in 20%, urticaria in 20%, and irritation in 10% of patients. Importantly, the majority of these reactions were classified as mild in severity.

The SS-31 peptide’s mechanism of selectively targeting dysfunctional mitochondria while having no effects on healthy mitochondria contributes to its favorable safety profile in research settings. This selectivity stems from SS-31 peptide’s interaction with cardiolipin in the context of mitochondrial stress, where the peptide appears to preferentially accumulate in mitochondria with compromised function.

Research Applications and Future Directions for SS-31 Peptide

SS-31 peptide has received multiple regulatory designations recognizing its potential for treating mitochondrial diseases. The SS-31 peptide was granted Fast Track designation for treatment of primary mitochondrial myopathy in 2016, orphan drug designation for Barth Syndrome in 2017, and Fast Track designation for Leber’s Hereditary Optic Neuropathy in 2017. An expanded access program exists for patients with confirmed genetic defects underlying mitochondrial disease who exhibit serious clinical manifestations of mitochondrial dysfunction.

Beyond the conditions currently under clinical investigation, preclinical research has demonstrated SS-31 peptide benefits in models of cognitive impairment, atherosclerosis, osteoarthritis, diabetes, glaucoma, sepsis-induced organ dysfunction, and general aging processes. The SS-31 peptide’s ability to improve mitochondrial structure, function, and bioenergetics across multiple organ systems suggests broad applicability for investigating mitochondrial contributions to various pathophysiological states.

Mechanistic Research Opportunities

Current research priorities include further elucidating the molecular mechanisms by which SS-31 peptide-cardiolipin interactions influence respiratory chain supercomplex assembly, membrane potential regulation, and protein complex stability. The SS-31 peptide serves as a valuable tool for investigating how cardiolipin organization affects mitochondrial function and how restoration of proper cardiolipin-protein interactions can ameliorate disease phenotypes.

Additionally, research into potential synergistic effects between SS-31 peptide and other mitochondrial modulators, as well as investigations into how improvements in mitochondrial function might influence broader cellular signaling networks, represent active areas of scientific inquiry. Resources from the National Institutes of Health continue to support SS-31 peptide research across multiple disease models.

Conclusion

SS-31 peptide (elamipretide) represents a significant advancement in mitochondria-targeted research tools, offering a unique mechanism for investigating and potentially modulating mitochondrial dysfunction across diverse disease states. Its specific interaction with cardiolipin, favorable pharmacokinetic profile, and demonstrated effects in both preclinical models and clinical trials have established SS-31 peptide as an important compound for understanding mitochondrial contributions to human pathophysiology.

The SS-31 peptide’s FDA approval for Barth syndrome marks an important milestone, validating the therapeutic potential of directly targeting mitochondrial cardiolipin metabolism. While clinical results in other conditions have been mixed, the extensive preclinical research demonstrating SS-31 peptide benefits across cardiac, skeletal muscle, renal, and neurological systems continues to drive investigation into optimal applications and patient populations.

As research continues to uncover the complex interplay between mitochondrial function, cellular signaling, and disease progression, SS-31 peptide provides investigators with a powerful tool for dissecting these relationships and exploring new avenues for addressing conditions characterized by mitochondrial dysfunction. The compound’s relatively benign safety profile and well-characterized mechanisms make SS-31 peptide particularly valuable for both basic research and translational studies aimed at developing mitochondrial-targeted therapeutic strategies.

References

1. Russo S, De Rasmo D, Signorile A, Corcelli A, Lobasso S. Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in Tafazzin knockdown mice. Sci Rep. 2022;12:19847. doi:10.1038/s41598-024-64368-y
2. Chavez JD, Tang X, Campbell MD, et al. Mitochondrial protein interaction landscape of SS-31. Proc Natl Acad Sci USA. 2020;117(26):15363-15373. doi:10.1073/pnas.2002250117
3. Campbell MD, Duan J, Samuelson AT, et al. Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice. Free Radic Biol Med. 2019;134:268-281.
4. Wang X, Su J, Huang H, et al. Application research of novel peptide mitochondrial-targeted antioxidant SS-31 in mitigating mitochondrial dysfunction. Biomed Pharmacother. 2024;171:116163. doi:10.1016/j.biopha.2024.116163
5. Sabbah HN, Gupta RC, Singh-Gupta V, Zhang K, Lanfear DE. Abnormalities of mitochondrial dynamics in the failing heart: Normalization following long-term therapy with elamipretide. Cardiovasc Drugs Ther. 2018;32(4):319-328.
6. Chatfield KC, Sparagna GC, Sucharov CC, et al. Elamipretide improves mitochondrial function in the failing human heart. JACC Basic Transl Sci. 2019;4(2):147-157.
7. Daubert MA, Yow E, Dunn G, et al. Novel mitochondria-targeting peptide in heart failure treatment: A randomized, placebo-controlled trial of elamipretide. Circ Heart Fail. 2017;10(12):e004389.
8. Vernon HJ. FDA approves drug for treatment of rare mitochondrial disorder. Johns Hopkins Medicine News. 2025. Available at: https://hub.jhu.edu/2025/09/25/fda-approves-barth-syndrome-treatment/
9. Pharaoh G, Kamat V, Kannan S, et al. The mitochondrially targeted peptide elamipretide (SS-31) improves ADP sensitivity in aged mitochondria by increasing uptake through the adenine nucleotide translocator (ANT). Geroscience. 2023;45(6):3529-3548. doi:10.1007/s11357-023-00861-y
10. Liu S, Soong Y, Seshan SV, Szeto HH. SS-31, a mitochondria-targeting peptide, ameliorates kidney disease. Kidney Int. 2022;91(6):1311-1325.
11. Allen ME, Pennington ER, Perry JB, et al. Contemporary insights into elamipretide’s mitochondrial mechanism of action and therapeutic effects. Biomed Pharmacother. 2025;173:116428. doi:10.1016/j.biopha.2025.116428
12. Care A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007;13(5):613-618. doi:10.1038/nm1582
13. Abdellatif M. The role of microRNA-133 in cardiac hypertrophy uncovered. Circ Res. 2010;106(1):16-18. doi:10.1161/circresaha.109.212183
14. Matkovich SJ, Wang W, Tu Y, et al. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res. 2010;106(1):166-175.
15. Liu N, Bezprozvannaya S, Williams AH, et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev. 2008;22(23):3242-3254.
16. Dong DL, Chen C, Huo R, et al. Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: A novel mechanism for progressive cardiac hypertrophy. Hypertension. 2010;55(4):946-952.
17. Xu Y, Fang H, Xu Q, et al. microRNA-133: expression, function and therapeutic potential in muscle diseases and cancer. Curr Drug Targets. 2014;15(8):817-828.
18. Peptide Sciences. MiR-133a, Hypertrophy, SS-31, and PE-22-28: How Do They Work? Available at: https://www.peptidesciences.com/peptide-research/mir-133a-hypertrophy-ss31-pe2228